Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

An essential role of IκBζ in the transcriptional program in Th17 development

Authors: Kazuo Okamoto, Masatsugu Oh-hora, Hiroshi Takayanagi

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

IL-17-producing helper T (Th17) cells are a distinct T cell subset characterized by its pathological role in autoimmune diseases. Our group previously showed that Th17 cells function as osteoclastogenic helper T cells in bone destruction associated with inflammation, and that inhibition of Th17 development has the potential of a beneficial impact on bone diseases including rheumatoid arthritis (RA) [1]. It is therefore important to comprehend the molecular mechanism underlying Th17 development in order to develop ideal therapeutic strategies against RA. …
Literature
1.
Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006, 203: 2673-2682. 10.1084/jem.20061775.PubMedCentralCrossRefPubMed
2.
Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, Ohya K, Jetten AM, Akira S, Muta T, Takayanagi H: IκBζ regulates TH17 development by cooperating with ROR nuclear receptors. Nature. 2010, 464: 1381-1385. 10.1038/nature08922.CrossRefPubMed
Metadata
Title
An essential role of IκBζ in the transcriptional program in Th17 development
Authors
Kazuo Okamoto
Masatsugu Oh-hora
Hiroshi Takayanagi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3691

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Poster presentation

SPACIA1/SAAL1: a newly identified gene associated with aberrant proliferation of synovial fibroblasts

Poster presentation

Reconstruction of injured spinal cord by epigenetic regulation of transplanted neural stem cells

Poster presentation

Abnormal expressions of immune response-related genes in RA bone marrow cells

Poster presentation

Pilocarpine suppresses hyperalgesia induced by intermittent cold stress (ICS) as an experimental fibromyalgia model in mice

Poster presentation

Features of rheumatic fever in adult patients in modern Kyrgyzstan

Poster presentation

PTEN in antigen presenting cells is a master regulator for Th17-mediated autoimmune pathology
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits